Core Viewpoint - The company reported better-than-expected performance for 1H25, driven by smooth project progress, commercialization ramp-up, and improved operational efficiency [1] Financial Performance - Revenue for 1H25 reached 9.95 billion yuan, a year-on-year increase of 16.1%, with continuing operations revenue up by 20.2% [1] - Gross margin stood at 42.7%, an increase of 3.6 percentage points year-on-year [1] - Adjusted EBITDA was 4.31 billion yuan, up 20.6% year-on-year, corresponding to a profit margin of 43.3% [1] - Adjusted net profit reached 2.84 billion yuan, a year-on-year increase of 11.6%, with a corresponding profit margin of 28.5% [1] - The company raised its revenue growth forecast for 2025 to 14%-16% and indicated steady profit level improvements and significant free cash flow growth [1] Business Development Trends - The CRDMO business model is fully operational, with over 50 molecular projects empowered as of 1H25, and potential milestone payments reaching 9 billion USD [2] - Revenue from preclinical stage projects was 4.15 billion yuan, a year-on-year increase of 35.2%, driven by research services and preclinical development project revenue conversion [2] - Revenue from Phase III clinical and commercialization stages was 4.29 billion yuan, up 24.9% year-on-year, benefiting from the advancement of early projects and ongoing commercialization [2] - The company has 67 Phase III clinical projects and 24 commercialization projects as of 1H25, with 25 PPQ projects scheduled for 2025 [2] - A total of 86 new projects were signed in 1H25, with over 70% being bispecific, multi-specific, and ADCs, showcasing the company's complex molecular technology capabilities [2] - The company secured 9 new molecules in 1H25, including 2 Phase III projects, primarily from the U.S. [2] - The backlog of uncompleted orders reached 20.3 billion USD, with approximately 4.2 billion USD in orders not completed within three years [2] Global Capacity Expansion - Capital expenditure for 1H25 was approximately 1.9 billion yuan, with an expected total of 5.3 billion yuan for the year [3] - In Singapore, the modular biopharmaceutical (DP) production facility has commenced construction, while the modular raw material (DS) production facility is in the design phase [3] - In Ireland, MFG6.2 has completed its first engineering batch and PPQ production, while MFG7 has completed its second 12kL scale PPQ production [3] - In the U.S., construction of MFG11 is ongoing, providing end-to-end R-D-M services [3] - In China, the 15kL raw material production line in Hangzhou has completed its first commercial PPQ production, and the Chengdu microbial commercialization base has officially started construction [3] Profit Forecast and Valuation - Due to smooth project progress and improved operational efficiency, the company raised its net profit forecast for 2025/2026 by 5.5%/1.6% to 4.21/4.71 billion yuan [3] - Adjusted profit forecasts for 2025/2026 were increased by 2.5%/4.1% to 5.11/5.58 billion yuan [3] - The company maintains an outperform rating, with the current stock price corresponding to adjusted P/E ratios of 21.7x/19.6x for 2025/2026 [3] - The target price was raised by 10.8% to 36 HKD, corresponding to adjusted P/E ratios of 26.3x/23.7x for 2025/2026, indicating a potential upside of 20.9% from the current stock price [3]

Core Viewpoint - The company has raised its profit forecasts for 2025/2026 due to smooth project progress and improved operational efficiency, maintaining an outperform rating in the industry [1] Financial Performance - The company reported 1H25 revenue of 9.95 billion, a year-on-year increase of 16.1%, with a continuous operating business revenue growth of 20.2% [2] - Gross margin reached 42.7%, up 3.6 percentage points year-on-year, while adjusted EBITDA was 4.31 billion, reflecting a 20.6% increase [2] - Adjusted net profit for 1H25 was 2.84 billion, a year-on-year increase of 11.6%, with a corresponding profit margin of 28.5% [2] Business Model and Growth - The CRDMO business model is fully operational, with over 50 molecular projects enabled, and potential milestone payments reaching 9 billion [3] - Revenue from preclinical stage projects was 4.15 billion, up 35.2% year-on-year, driven by research services and preclinical development project conversions [3] - Revenue from clinical phase III and commercialization reached 4.29 billion, a 24.9% increase, supported by the advancement of early projects and ongoing commercialization [3] Project and Order Status - The company signed 86 new projects in 1H25, with over 70% being complex molecules, showcasing its technical capabilities [4] - The company secured 9 new molecular projects, including 2 clinical phase III projects, primarily from the U.S. [4] - The total unfulfilled orders reached 20.3 billion, with approximately 4.2 billion in orders expected to be completed within three years [4] Capacity Expansion - Capital expenditure for 1H25 was approximately 1.9 billion, with an expected total of 5.3 billion for the year [5] - In Singapore, the modular biopharmaceutical production facility has commenced construction, while the modular bulk production facility is in the design phase [5] - In Ireland, the MFG6.2 facility has completed its first engineering batch and PPQ production, and MFG7 has completed its second 12kL scale PPQ production [5]

中金发布研报称，由于药明生物(02269)项目推进顺利以及经营效率提升，上调2025/2026归母净利润预 测5.5%/1.6%至42.1/47.1亿元，上调2025/2026经调整利润预测2.5%/4.1%至51.1/55.8亿元。维持跑赢行业 评级，当前股价对应2025/2026年经调整P/E为21.7x/19.6x。由于医药板块近期估值中枢上移，该行上调 目标价10.8%至36港元，对应2025/2026年经调整P/E为26.3x/23.7x，较当前股价有20.9%上行空间。 中金主要观点如下： 1H25业绩超过该行预期 公司公布1H25业绩：收入99.5亿元，同比+16.1%，持续经营业务收入+20.2%;毛利率42.7%，同比 +3.6ppt;经调整EBITDA43.1亿元，同比+20.6%，对应利润率43.3%;经调整纯利28.4亿元，同比+11.6%， 对应利润率28.5%。超过该行预期，主要因项目推进顺利、商业化项目爬坡、以及经营效率提升。公司 上调2025年收入增速预期至14%-16%，同时指引盈利水平稳步提升以及自由现金流显著增长。 CRDMO商业模式全面发力 1H25，1)R：截至1H2 ...

Financial Data and Key Metrics Changes - Revenue reached nearly RMB 10 billion, representing a 16.1% increase year-over-year [28] - Adjusted EBITDA increased by 20.6% to RMB 4.3 billion, with an adjusted EBITDA margin of 43.3% [35][36] - Adjusted net profit exceeded RMB 2.8 billion, reflecting an 11.6% year-over-year increase [36] - Gross profit margin improved from 39.1% to 42.7%, with adjusted gross profit margin at 45.6% [7][40] Business Line Data and Key Metrics Changes - Research and Development (R&D) revenue grew over 35% year-over-year, driven by a strong pipeline of projects [30] - Late-phase and commercial manufacturing revenue grew close to 25%, representing over 43% of the total portfolio [30] - Early-phase revenue saw a decline due to timing issues with large-scale clinical manufacturing projects transitioning from phase two to phase three [30][31] Market Data and Key Metrics Changes - North America accounted for nearly 60% of revenue, with a growth rate of 20% [23] - Europe contributed close to 20% of revenue, showing modest growth as the company shifts focus from CMO projects to early-phase programs [24] - China represented 13% of revenue, experiencing a single-digit decline primarily due to out-licensing of programs to global partners [25] - Asia, particularly Japan, Korea, and Singapore, showed significant growth, now accounting for nearly 7% of revenue with more than double the growth rate [26] Company Strategy and Development Direction - The company emphasizes a unique CRDMO model, focusing on both service-based and IP-driven revenue streams [50][57] - The strategy includes expanding capacity globally, with significant investments in facilities in the US, Ireland, and Singapore [47][79] - The company aims to leverage its strong portfolio in ADCs and bispecifics, which now account for over 40% of its project portfolio [22] Management's Comments on Operating Environment and Future Outlook - Management noted that the company has absorbed post-COVID industry adjustments and is positioned for accelerated growth [28] - The backlog has shown significant growth, with milestone backlog increasing from RMB 7 billion to RMB 9 billion and service backlog from RMB 10 billion to RMB 11.3 billion [16][17] - The company expects to continue benefiting from global biotech trends, including M&A activities and out-licensing of Chinese assets to global partners [63][64] Other Important Information - The company achieved a 100% success rate in regulatory inspections, hosting 44 inspections [6] - Employee retention rate remains high at 98.8%, with no increase in total employee numbers over the past 18 months [42] - The company has a strong cash position with RMB 12.5 billion on hand and a conservative debt level of RMB 2.7 billion [43][47] Q&A Session Summary Question: What are the key drivers for revenue growth in the upcoming quarters? - Management highlighted the successful execution of the follow and win molecule strategies, with a strong pipeline of late-phase projects expected to ramp up [29] Question: How does the company plan to address the decline in early-phase revenue? - The decline is attributed to timing issues with large-scale projects transitioning to manufacturing, which is expected to be replenished by new projects in the pre-IND space [30][31] Question: What is the company's outlook on the global market trends? - Management expressed confidence in continued growth driven by M&A activities and the out-licensing of Chinese biotech programs to global partners, which typically results in significant revenue amplification [63][64]

8月19日，药明生物(02269)公布其2025年中期业绩，公司当期实现收益99.5亿元(人民币，单位下同)， 同比增长16.1%;当期毛利率同比提升3.6个百分点，至42.7%;纯利同比增长54.8%至27.6亿元，此带动公 司拥有人应占纯利增长56.0%至人民币23.4亿元，对应经调整纯利同比增长11.6%至人民币28.4亿元。与 此同时，药明生物宣布上调2025年全年收入指引至14%-16%。 从业务结构看，从研发(R)到开发(D)再到生产(M)的加速转化成为公司高速增长的关键驱动力。智通财 经APP了解到，2025年上半年药明生物新签86个综合项目，刷新同期历史纪录，推动综合项目数攀升至 864个。其中，临床III期和商业化项目分别增至67和24个，临床III期及商业化生产收益同比增24.9%。 进一步来看，新增项目中超70%聚焦ADC(抗体偶联药物)与双抗/多抗领域。这一结构既印证了两大赛道 的高景气度，更凸显药明生物对生物药高潜力领域的精准卡位：其在R端业务的布局，使其能够更早、 更精准地抓住前沿创新疗法机遇，稳定占据优势竞争生态位，持续为D和M输送增长动能，是业务护城 河的具象化体现。 订单储备 ...

8月19日，药明生物(02269)公布其2025年中期业绩，公司当期实现收益99.5亿元(人民币，单位下同)， 同比增长16.1%;当期毛利率同比提升3.6个百分点，至42.7%;纯利同比增长54.8%至27.6亿元，此带动公 司拥有人应占纯利增长56.0%至人民币23.4亿元，对应经调整纯利同比增长11.6%至人民币28.4亿元。与 此同时，药明生物宣布上调2025年全年收入指引至14%-16%。 从业务结构看，从研发(R)到开发(D)再到生产(M)的加速转化成为公司高速增长的关键驱动力。智通财 经 APP 了解到，2025年上半年药明生物新签86个综合项目，刷新同期历史纪录，推动综合项目数攀升 至 864 个。其中，临床III期和商业化项目分别增至67和24个，临床III期及商业化生产收益同比增 24.9%。 进一步来看，新增项目中超 70% 聚焦 ADC(抗体偶联药物)与双抗/多抗领域。这一结构既印证了两大赛 道的高景气度，更凸显药明生物对生物药高潜力领域的精准卡位：其在R端业务的布局，使其能够更 早、更精准地抓住前沿创新疗法机遇，稳定占据优势竞争生态位，持续为D和M输送增长动能，是业务 护城河的具象化 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） 藥 明 合 聯 生 物 技 術 有 限 公 司* （股份代號：2268） 內幕消息 2025年中期業績簡報 本公 告由藥 明合 聯生物 技術有 限公司 *（「本 公司」）根據香 港聯 合交易 所有限 公司 證 券 上 市 規 則（「 上 市 規 則 」）第 13.09 條 以 及 香 港 法 例 第 571 章 證 券 及 期 貨 條 例 第 XIVA部項下的內幕消息條文（ 定義見上市規則 ）而刊發。 為使本公司股東及有意投資者能夠更深入、更全面地了解其2025年中期業績及業 務 營 運 ， 本 公 司 將 於 2025 年 8 月 19 日 上 午 八 時 三 十 分 及 下 午 八 時 三 十 分（ 香 港 時 間 ）召 開 電 話 會 議 ， 屆 時 將 就 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [2][10]. Core Views - The TIDES business segment has shown remarkable performance, leading to an upward revision of the full-year revenue guidance [10]. - For the first half of 2025, the company reported a revenue of 20.799 billion RMB, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion RMB, a year-on-year increase of 101.92% [4]. - The company expects revenue growth for its continuing operations to return to double digits, with the growth rate revised from 10-15% to 13-17% [8]. Financial Performance - In H1 2025, the gross margin improved significantly to 44.45%, an increase of 5.08 percentage points year-on-year, while the net profit margin rose to 41.64%, up 16.81 percentage points year-on-year [5]. - The revenue from the chemical business reached 16.3 billion RMB, a growth of 33.5%, while the TIDES business revenue surged to 5.03 billion RMB, a staggering increase of 141.6% [6]. - The company’s total orders on hand reached 56.69 billion RMB, reflecting a year-on-year growth of 37.2% [8]. Revenue and Profit Forecast - The revenue forecast for 2025-2027 has been adjusted to 43.299 billion RMB, 49.656 billion RMB, and 56.472 billion RMB respectively, with net profit forecasts revised to 14.406 billion RMB, 13.249 billion RMB, and 15.249 billion RMB [10][12]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 5.02 RMB, 4.61 RMB, and 5.31 RMB respectively [10].

Financial Data and Key Metrics Changes - The company's total revenue for the first half of 2025 reached RMB 20.8 billion, with revenue from continuing operations growing 24.2% year over year to RMB 20.4 billion [7] - Adjusted non-IFRS net profit increased 44.4% year over year to RMB 6.31 billion, with a non-IFRS net profit margin of 30.4% [7][26] - The adjusted IFRS gross profit margin improved from 41.6% in 2024 to 44.5% in the first half of 2025 [26] Business Line Data and Key Metrics Changes - WuXi Chemistry's CRDMO revenue grew 33.5% year over year to RMB 16.3 billion, with an adjusted non-IFRS gross profit margin of 49% [12] - The small molecule DNM business revenue grew 17.5% year over year to RMB 8.68 billion [13] - WuXi Testing revenue slightly declined to RMB 2.69 billion in the first half, while lab testing revenue reached RMB 1.89 billion, almost flat year over year [19][20] - WuXi Biology revenue increased 7.1% year over year to RMB 1.25 billion, with a gross profit margin of 36.4% [23] Market Data and Key Metrics Changes - Revenue from US companies grew 38.4% year over year, while European companies grew 9.2% and Japan, Korea, and other regions grew 7.6% [9][10] - China experienced a decline in revenue, indicating a diversified revenue stream that supports financial stability [10] Company Strategy and Development Direction - The company focuses on enhancing core capabilities and expanding capacity to meet customer needs, with a record backlog for continuing operations growing 37.2% year over year [8][30] - The company is committed to sustainability, achieving a triple A rating from MSCI and validating emissions reduction targets [11] - The full-year guidance for continuing operations revenue has been raised to a growth rate of 13% to 17% for 2025, up from the previous 10% to 15% [31] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic global macro environment with uncertainties but remains confident in the demand for enabling services [30] - The company expects to further improve the adjusted non-IFRS net profit margin in 2025 and anticipates free cash flow to increase from RMB 5 billion to RMB 6 billion [32] - Management emphasizes the importance of retaining top talent and enhancing business resilience [34] Other Important Information - The company distributed a total of RMB 3.84 billion in cash dividends in 2025, including a special cash dividend [33] - The company completed share repurchases worth RMB 1.1 billion in the first half and plans additional repurchases [33][34] Q&A Session Summary Question: What are the key drivers for the second quarter revenue and earnings exceeding expectations? - Management attributes the strong performance to high execution efficiency rather than customer front-loading orders due to tariffs [39] Question: What considerations led to the raised full-year guidance? - The guidance was raised due to operational momentum and expectations of near double-digit growth in the second half despite external uncertainties [40] Question: How should new order growth be interpreted? - New orders signed in Q2 increased by approximately 12% year over year, indicating strong growth momentum [44] Question: What is the impact of tariffs on customer behavior? - There have not been significant changes in customer behavior due to tariffs, as the global pharmaceutical supply chain remains complex [57] Question: What is the outlook for early-stage project demand? - Early-stage lab services remain stable, with robust demand for new orders despite overall challenges in the biotech funding environment [54] Question: How does the company view the growth potential of its pipeline? - The company has several promising projects in its pipeline, including those in the GLP-1 category, which are expected to drive future growth [49][51]

Financial Data and Key Metrics Changes - The company's total revenue for H1 2025 reached RMB 20.8 billion, with revenue from continuing operations growing 24.2% year over year to RMB 20.4 billion [7] - Adjusted non-IFRS net profit increased 44.4% year over year to RMB 6.31 billion, with a net profit margin of 30.4% [7][25] - The adjusted IFRS gross profit margin improved from 41.6% in 2024 to 44.5% in H1 2025 [25] Business Line Data and Key Metrics Changes - WuXi Chemistry's revenue grew 33.5% year over year to RMB 16.3 billion, with an adjusted non-IFRS gross profit margin of 49% [11] - Revenue from the small molecule DNM business grew 17.5% year over year to RMB 8.68 billion [12] - WuXi Testing revenue slightly declined to RMB 2.69 billion in H1 2025, with lab testing services revenue reaching RMB 1.89 billion, almost flat year over year [18][19] - WuXi Biology revenue increased 7.1% year over year to RMB 1.25 billion, with a gross profit margin of 36.4% [22] Market Data and Key Metrics Changes - Revenue from US companies grew 38.4% year over year, while revenue from European companies grew 9.2% and revenue from Japan, Korea, and other regions grew 7.6% [8] - China experienced a decline in revenue, indicating a diversified revenue stream that supports financial stability [9] Company Strategy and Development Direction - The company focuses on enhancing core capabilities and expanding capacity to meet customer needs, with a record backlog for continuing operations growing 37.2% year over year [8][10] - The company aims to accelerate global expansion and capacity building while promoting lean management and operational efficiency [29] - Full year guidance for continuing operations revenue has been raised to a growth rate of 13% to 17% [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic and complex global macro environment but expresses confidence in the company's operational execution and customer demand [29] - The company anticipates continued growth in late-stage clinical and commercial projects, contributing to sustained business growth [29][31] Other Important Information - The company achieved a triple-A rating from MSCI for the first time, marking a significant milestone in sustainability efforts [10] - Cash dividends distributed in 2025 totaled RMB 3.84 billion, with share repurchases amounting to RMB 1.1 billion in the first half [32][33] Q&A Session Summary Question: What are the key drivers for the second quarter revenue and earnings exceeding expectations? - Management clarified that the outperformance was due to high operational efficiency and not customer front-loading orders due to tariffs [38] Question: What considerations led to the raised full year guidance? - The company noted that despite uncertainties, operational momentum and capacity validation were key factors in raising guidance [39] Question: How should new order growth be interpreted? - New orders signed in Q2 increased by approximately 12% year over year, indicating strong growth momentum [43] Question: What is the outlook for margin improvement in the second half? - Management expects margin improvement due to increased delivery of large late-stage and commercial orders, along with the divestiture of loss-making businesses [47] Question: How is the company addressing pricing impacts in the testing business? - The company maintains competitive pricing while emphasizing the need for high-quality services, despite price competition in the market [70] Question: What is the impact of tariffs on customer behavior? - Management has not observed significant changes in customer behavior due to tariffs, focusing instead on delivering high-quality services [57]